Jason S. Lewis

Jason S. Lewis
BornFebruary 1970 (age 56)
Liss, England
Alma materUniversity of Essex
University of Kent
OccupationsRadiochemist, professor
Scientific career
FieldsMolecular Imaging, radiochemistry
WorkplacesWashington University in St. Louis
Memorial Sloan Kettering Cancer Center
Cornell University

Jason S. Lewis is a British radiochemist whose work relates to oncologic therapy and diagnosis. His research focus is a molecular imaging-based program focused on radiopharmaceutical development as well as the study of multimodality (PET, CT & MRI) small- and biomolecule-based agents and their clinical translation.[1] He has worked on the development of small molecules as well as radiolabeled peptides and antibodies probing the overexpression of receptors and antigens on tumors.[2]

Education

Jason S. Lewis was born and raised in Horndean, Hampshire, England. Lewis received his Bachelor of Science in chemistry, B.Sc. from the University of Essex in 1992. He received his Master of Science in chemistry from the University of Essex in 1993.

In 1996, he received his Doctor of Philosophy in Biochemistry at the University of Kent.

Career

Lewis taught Radiology at the Washington University School of Medicine, Mallinckrodt Institute of Radiology from 2000 to 2008. He is the Emily Tow Jackson Chair in Oncology, the Vice Chairman for Research (Radiology) and Chief Attending of the Radiochemistry and Imaging Sciences Service at Memorial Sloan Kettering Cancer Center. He also heads a laboratory in the Sloan Kettering Institute's Molecular Pharmacology Program and is a professor at the Gerstner Sloan Kettering Graduate School of Biomedical Sciences.[3][4]

Lewis holds joint appointments in the Departments of Radiology and the Department of Pharmacology at Weill Cornell Medical School, NY.

Research focus

Lewis is a proponent of development imaging tools for use in personalized medicine. Lewis designs and develops radiochemical probes for use in nuclear medicine as well as multi-modality molecular imaging.[5] The use of these probes span from oncological metabolic detection to understanding the biological processes of cancer and pharmacological modification. These probes can be used for biomarkers in clinical trials as well as used as an agent for oncological diagnostics.[6][7] He has developed multiple new small molecules that target tumor metabolism, as well as radiolabeled peptides and antibodies for use in probing overexpression of receptors and antigens on tumors for research, clinical trials and in the clinic.[8]

Recognition

Editorial board memberships

Selected Publications

  • Pratt EC, Mandleywala K, Bauer D, Bolaender A, Chao G, Castanares MA, Collins EC, Lewis JS. ImmunoPET for mesothelin positive tissues using bio-orthogonal in-vivo click chemistry. Nucl Med Biol. 2025 Jul 15;148-149:109051. doi: 10.1016/j.nucmedbio.2025.109051. [Epub ahead of print] PubMed PMID: 40694891; PubMed Central PMCID: PMC12328198.
  • Mack KN, Bauer D, Carter LM, Carrasco SE, Atmane MI, Viray TD, Brooks CL, Hollingsworth MA, Radhakrishnan P, Lewis JS. Pretargeted alpha therapy in MUC16-positive high-grade serous ovarian cancer. Nucl Med Biol. 2025 Jan-Feb;140-141:108976. doi: 10.1016/j.nucmedbio.2024.108976. Epub 2024 Nov 22. PubMed PMID: 39615062; PubMed Central PMCID: PMC12404150.
  • Mahajan S, Grkovski M, Staton KD, Ravassa S, Domfe K, Strauss HW, Humm JL, Zanzonico PB, Beattie BJ, Cho I, Burnazi EM, Fox JJ, Schöder H, Osborne JR, Youn T, Jhaveri K, Chiosis G, Dunphy MP. Epichaperome-targeted myocardial imaging by (124)I-PU-H71 PET. Clin Transl Imaging. 2024 Dec;12(6):619-627. doi: 10.1007/s40336-024-00658-9. Epub 2024 Sep 20. PubMed PMID: 39935517; PubMed Central PMCID: PMC11810128.
  • Bauer D, De Gregorio R, Pratt EC, Bell A, Michel A, Lewis JS. Examination of the PET in vivo generator (134)Ce as a theranostic match for (225)Ac. Eur J Nucl Med Mol Imaging. 2024 Nov;51(13):4015-4025. doi: 10.1007/s00259-024-06811-w. Epub 2024 Jun 28. PubMed PMID: 38940841; PubMed Central PMCID: PMC12121724.
  • Sarrett SM, Rodriguez C, Delaney S, Hosny MM, Sebastiano J, Santos-Coquillat A, Keinänen OM, Carter LM, Lastwika KJ, Lampe PD, Zeglis BM. Evaluating CD133 as a Radiotheranostic Target in Small-Cell Lung Cancer. Mol Pharm. 2024 Mar 4;21(3):1402-1413. doi: 10.1021/acs.molpharmaceut.3c01063. Epub 2024 Feb 8. PubMed PMID: 38331430; PubMed Central PMCID: PMC10915790.
  •  Arroyo A, Lyashchenko SK, Lewis JS. Methods for the Production of Radiolabeled Bioagents for ImmunoPET. Methods Mol Biol. 2024;2729:117-142. doi: 10.1007/978-1-0716-3499-8_8. Review. PubMed PMID: 38006494; PubMed Central PMCID: PMC11330323.
  • Chiosis G, Digwal CS, Trepel JB, Neckers L. Structural and functional complexity of HSP90 in cellular homeostasis and disease. Nat Rev Mol Cell Biol. 2023 Nov;24(11):797-815. doi: 10.1038/s41580-023-00640-9. Epub 2023 Jul 31. Review. PubMed PMID: 37524848; PubMed Central PMCID: PMC10592246.
  •  Zeglis BM, Lewis JS. Click Here for Better Chemistry. N Engl J Med. 2022 Dec 15;387(24):2291-2293. doi: 10.1056/NEJMcibr2213596. Epub 2022 Nov 30. PubMed PMID: 36449446; PubMed Central PMCID: PMC10501737.
  • Ginsberg SD, Sharma S, Norton L, Chiosis G. Targeting stressor-induced dysfunctions in protein-protein interaction networks via epichaperomes. Trends Pharmacol Sci. 2023 Jan;44(1):20-33. doi: 10.1016/j.tips.2022.10.006. Epub 2022 Nov 20. Review. PubMed PMID: 36414432; PubMed Central PMCID: PMC9789192.
  • Maitz CA, Delaney S, Cook BE, Genady AR, Hoerres R, Kuchuk M, Makris G, Valliant JF, Sadeghi S, Lewis JS, Hennkens HM, Bryan JN, Zeglis BM. Pretargeted PET of Osteodestructive Lesions in Dogs. Mol Pharm. 2022 Sep 5;19(9):3153-3162. doi: 10.1021/acs.molpharmaceut.2c00220. Epub 2022 May 30. PubMed PMID: 35635337; PubMed Central PMCID: PMC10316029.

References

  1. ↑ "Professor Jason Lewis joins Clarity Pharmaceuticals' Advisory Board". Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging. 2018-10-11. Retrieved 2019-06-07.
  2. ↑ Lewis, Jason S.; Evans, Michael J.; Fox, Ian L.; Caen, Jonathan D.; Dilling, Thomas R.; Dacek, Megan M.; Henry, Kelly E. (2019-01-01). "A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer". Clinical Cancer Research. 25 (1): 166–176. doi:10.1158/1078-0432.CCR-18-1485. ISSN 1078-0432. PMC 6320277. PMID 30228208.
  3. ↑ "Jason S. Lewis". Memorial Sloan Kettering Cancer Center. Retrieved 2019-06-07.
  4. ↑ "Our Faculty". Memorial Sloan Kettering Cancer Center. Retrieved 2019-06-17.
  5. ↑ "The Jason Lewis Lab". Memorial Sloan Kettering Cancer Center. Retrieved 2019-06-07.
  6. ↑ Lewis, Jason S.; Livingston, Philip O.; Scholz, Wolfgang W.; Sawada, Ritsuko; Ragupathi, Govind; Drobjnak, Marija; Sevak, Kuntal K.; Evans, Michael J.; Wu, Xiaohong (2013-11-01). "Applying PET to Broaden the Diagnostic Utility of the Clinically Validated CA19.9 Serum Biomarker for Oncology". Journal of Nuclear Medicine. 54 (11): 1876–1882. doi:10.2967/jnumed.113.119867. ISSN 0161-5505. PMC 4274751. PMID 24029655.
  7. ↑ Viola-Villegas, Nerissa Therese; Carlin, Sean D.; Ackerstaff, Ellen; Sevak, Kuntal K.; Divilov, Vadim; Serganova, Inna; Kruchevsky, Natalia; Anderson, Michael; Blasberg, Ronald G. (2014-05-20). "Understanding the pharmacological properties of a metabolic PET tracer in prostate cancer". Proceedings of the National Academy of Sciences of the United States of America. 111 (20): 7254–7259. Bibcode:2014PNAS..111.7254V. doi:10.1073/pnas.1405240111. ISSN 1091-6490. PMC 4034234. PMID 24785505.
  8. ↑ Lewis, Jason S.; Evans, Michael J.; Edwards, Kimberly J.; Abdel-Atti, Dalya; Dilling, Thomas R.; Henry, Kelly E. (2018-01-01). "Noninvasive 89Zr-Transferrin PET Shows Improved Tumor Targeting Compared with 18F-FDG PET in MYC-Overexpressing Human Triple-Negative Breast Cancer". Journal of Nuclear Medicine. 59 (1): 51–57. doi:10.2967/jnumed.117.192286. ISSN 0161-5505. PMC 5750524. PMID 28848040.
  9. ↑ ACADAdmin (2017-01-08). "2014 Distinguished Investigators". The Academy for Radiology & Biomedical Imaging Research. Retrieved 2019-08-20.
  10. ↑ "Fellows | World Molecular Imaging Society". www.wmis.org. 23 August 2013. Retrieved 2019-08-20.
  11. ↑ "2017 Award Recipients - SNMMI". www.snmmi.org. Retrieved 2019-08-20.
  12. ↑ "Jason Lewis Receives SNMMI Award - The ASCO Post". www.ascopost.com. Retrieved 2019-08-20.
  13. ↑ "Society of Nuclear Medicine and Molecular Imaging Announces 2019 Fellows - SNMMI". www.snmmi.org. Retrieved 2019-08-20.
  14. ↑ "Molecular Imaging and Biology - incl. option to publish open access (Editorial Board)". springer.com. Retrieved 2019-06-07.
  15. ↑ "JNM -- The Journal of Nuclear Medicine Editorial Board". jnm.snmjournals.org. Archived from the original on 2019-05-28. Retrieved 2019-06-07.
  16. ↑ Demoin, Dustin Wayne; Wyatt, Linden C.; Edwards, Kimberly J.; Abdel-Atti, Dalya; Sarparanta, Mirkka; Pourat, Jacob; Longo, Valerie A.; Carlin, Sean D.; Engelman, Donald M. (2016-09-21). "PET Imaging of Extracellular pH in Tumors with 64Cu- and 18F-Labeled pHLIP Peptides: A Structure–Activity Optimization Study". Bioconjugate Chemistry. 27 (9): 2014–2023. doi:10.1021/acs.bioconjchem.6b00306. ISSN 1043-1802. PMC 5034329. PMID 27396694.
  17. ↑ Nuclear Medicine and Biology Editorial Board.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.